Mingyao Li, PhD, Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania.
Peter Mueller, PhD, Department of Mathematics, Department of Statistics and Data Sciences, University of Texas at Austin
Lu Mao, PhD, Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison
Snehalata Huzurbazar, PhD, Department of Biostatistics, West Virginia University
Meetings of the Eastern North American Region of the International Biometric Society (a.k.a. "ENAR meetings") are held in late March or early April each year and reflect the broad interests of the Society, including both quantitative techniques and application areas. Faculty and student presenters from the Department of Biostatistics regularly participate giving invited talks, contributed talks, and poster presentations.
The Joint Statistical Meetings, known simply as "JSM", is the largest gathering of statisticians held annually in North American. Faculty and student presenters from the Department of Biostatistics regularly participate giving invited talks, contributed talks, and poster presentations. Our students often receive top awards and participate in the affiliated career marketplace at the event.
Biostatistics Seminar guest speaker, Michael Wallace, University of Waterloo, will present, "Dynamic treatment regimes and reward ignorant modelling".
Personalized medicine optimizes patient outcome by tailoring treatments to patient-level characteristics. This approach is formalized by dynamic treatment regimes (DTRs): decision rules that take patient information as input and output recommended treatment decisions. The DTR literature has seen the development of increasingly sophisticated causal inference techniques, which attempt to address the limitations of our typically observational datsaets. We note, however, that in practice most patients should often receive optimal or near-optimal treatment, and so the outcome used as part of a typical DTR analysis does not provide much additional information. In light of this, we propose reward ignorant modelling: ignoring the outcome and eliciting an optimal DTR by regressing the observed treatment on relevant covariates, as in a more standard analysis. We present some results from investigating this concept, and analysis of data from the International Warfarin Pharmacogenetics Consortium.
Last Updated On Friday, October 27, 2017 by Haydo, Amber LC
Created On Wednesday, August 09, 2017